While we have heard a lot about brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant – SAGE 217 or zuranolone – has been [...]
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on mitigating psychiatric relapse during pregnancy amidst the COVID-19 pandemic with Ob.Gyn News on [...]
Every Wednesday, we have the pleasure of holding virtual rounds with other clinicians to discuss important topics in reproductive psychiatry. So many great questions! Last week, one of our participants asked about using light therapy [...]
The American College of Obstetricians and Gynecologists (ACOG) now recommends screening for perinatal depression and anxiety, stating that “clinicians screen patients at least once during the perinatal period for depression and anxiety symptoms using a [...]
Perinatal psychiatry is a field in which we treat vulnerable patients, a mother and her child, where both the illness we are treating and the treatments we prescribe have the potential to affect the outcome. [...]
Previous research has shown that higher levels of depressive symptoms during pregnancy may be associated with lower levels of maternal-fetal attachment (MFA). Other studies have indicated that poor MFA is a significant predictor of worse [...]
Prozac (fluoxetine) was the first SSRI or selective serotonin reuptake inhibitor. Since its release in 1988, we have been gathering data on the reproductive safety of fluoxetine and other SSRIs. Over the last 32 years, [...]
For many women with bipolar disorder, lamotrigine (Lamictal) is an effective mood stabilizer. Given its favorable reproductive safety profile, lamotrigine is a reasonable option for women who require treatment with a mood stabilizer during pregnancy. [...]
Clinical Update 2020: Lamotrigine (Lamictal) and Pregnancy Maintenance treatment with a mood stabilizer during pregnancy can significantly reduce the risk of relapse in women with bipolar disorder; however, many of the mood stabilizers commonly [...]
Nausea and vomiting of pregnancy (NVP) affects up to 80% of women during the first trimester. A smaller proportion of women (0.3%–3.0%) experience severe vomiting or hyperemesis gravidarum. While milder cases of nausea and [...]